Recurrent Childhood Soft Tissue Sarcoma Completed Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00077454Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsTreatment